Lucid Diagnostics (LUCD) to Post Quarterly Earnings on Thursday

Lucid Diagnostics (NASDAQ:LUCD) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Lucid Diagnostics to announce earnings of ($0.04) per share and revenue of $1.4320 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

Lucid Diagnostics (NASDAQ:LUCD) last announced its earnings results on Wednesday, May 13th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $1.26 million for the quarter, compared to analysts’ expectations of $1.38 million. On average, analysts expect Lucid Diagnostics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Lucid Diagnostics Stock Up 0.0%

Shares of NASDAQ:LUCD opened at $0.96 on Wednesday. The firm has a market cap of $195.21 million, a price-to-earnings ratio of -2.05 and a beta of 1.08. Lucid Diagnostics has a 12 month low of $0.86 and a 12 month high of $1.63. The company’s fifty day simple moving average is $0.99 and its 200 day simple moving average is $1.13.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LUCD shares. Maxim Group lowered their target price on Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating for the company in a report on Friday, May 15th. Ascendiant Capital Markets upped their price objective on Lucid Diagnostics from $9.00 to $9.25 and gave the stock a “buy” rating in a research report on Monday, June 8th. Weiss Ratings upgraded Lucid Diagnostics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 4th. BTIG Research reissued a “buy” rating and issued a $2.50 target price on shares of Lucid Diagnostics in a research report on Friday, May 15th. Finally, Wall Street Zen cut Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Lucid Diagnostics currently has an average rating of “Moderate Buy” and an average price target of $4.19.

Insider Buying and Selling at Lucid Diagnostics

In related news, Director Dennis Matheis bought 245,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $1.00 per share, with a total value of $245,000.00. Following the completion of the transaction, the director owned 1,033,443 shares in the company, valued at $1,033,443. The trade was a 31.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new stake in Lucid Diagnostics during the fourth quarter worth $246,000. Millennium Management LLC bought a new position in shares of Lucid Diagnostics in the 4th quarter valued at about $168,000. Abel Hall LLC acquired a new position in shares of Lucid Diagnostics during the 4th quarter worth about $33,000. Squarepoint Ops LLC increased its stake in shares of Lucid Diagnostics by 1,871.7% during the 4th quarter. Squarepoint Ops LLC now owns 342,883 shares of the company’s stock worth $374,000 after purchasing an additional 325,493 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Lucid Diagnostics by 40.8% during the 4th quarter. Barclays PLC now owns 141,167 shares of the company’s stock worth $154,000 after purchasing an additional 40,891 shares during the last quarter. 74.01% of the stock is currently owned by institutional investors.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.